The emergence of mephedrone together with other artificial cathinones has presented problems for lawmakers and regulatory businesses tasked with managing the proliferation of recent psychoactive substances. The dynamic mother nature of artificial drug output, coupled with the power of chemists to change molecular constructions to evade legal constr